TABLE 2.
Some DL-derived, under investigation (under clinical trials) drug candidates.
| Organization (s) involved* | Name of under-investigation compound (code name of clinical-stage assets) | Detail | Refs |
|---|---|---|---|
| Exscientia and Sumitomo Dainippon Pharma (which has expertise in GPCR drug discovery) [Centaur Chemist] | DSP-1181 (in clinical trial phase I) | A potent full serotonin 5-HT1A receptor agonist with a lengthy half-life against obsessive-compulsive disorder | Mullard, (2017); Burki (2020) |
| DSP-0038 (in clinical trial phase I) | A dual-targeted agonist/antagonist for the 5-HT1a and 5-HT2a receptors against Alzheimer’s psychosis | Shimizu et al. (2022) | |
| Exscientia and Evotec [Centaur Chemist] | EXS-21546 (in clinical trial phase I) | An adenosine A2a receptor antagonist for immuno-oncology therapy for several tumor types | Shimizu et al. (2022) |
| Exscientia and one co-owner | GTAEXS617 (in clinical trial phase I) | A selective and highly potent inhibitor of CDK7, being investigated against transcriptionally addicted cancers | Besnard et al. (2022), Businesswire, (2023b) |
| Exscientia and Bristol Myers Squibb | EXS4318EXS4318 (in clinical trial phase I) | Against Inflammatory Diseases | Businesswire, (2023b); Businesswire, (2023c) |
| Exscientia, under a collaboration with Sumitomo Pharma, referred to as design as a service or DaaS | DSP-2342 Phase I clinical trial will commence soon | A bispecific small molecule dual 5-HT2A and 5-HT7 antagonist with broad potential in psychiatric disease | Exscientia (2023) |
| Recursion [Recursion OS] | REC-2282 (Phase 2/3 Trial) | A possibly first-in-disease, orally active, central nervous system penetrant small molecule histone deacetylase (HDAC) inhibitor to treat progressive neurofibromatosis type 2 (NF2)-mutated meningiomas | Jayatunga et al. (2022) |
| REC-4881 | An orally effective, non-ATP-competitive allosteric small molecule against MEK1 and MEK2 | Jayatunga et al. (2022) | |
| Insilico Medicine 3 [Pharma.AI platform (PandaOmics3.0 for novel target discovery, Chemistry42 2.0 for molecule generation and optimization with ADMET prediction, InClinico 1.0 for clinical trial prediction)] | ISM001-055 and INS018-055 (in clinical trial phase I and II, respectively) | Compounds against idiopathic pulmonary fibrosis | Kirkpatrick (2022), Nagra et al. (2023) |
| ISM3091 (in clinical trial phase I) | A ubiquitin-specific protease 1 (USP1) inhibitor that can potentially improve the result of cancer therapy by decreasing survivin levels and increasing DR5 through miR-216a-5p | BB (2023) | |
| ISM8207 (Phase I) (with Fosun Pharma) | A potentially first-in-class small molecule inhibitor of QPCTL for the treatment of advanced malignant tumors | Eurekalert (2023) | |
| Verge Genomics 4-5 [CONVERGE] | VRG50635 (in clinical trial phase I) The company only took 4 years to bring this compound from research to the clinical phase | As mentioned in the text | Businesswire (2022) |
| BenevolentAI [Benevolent Platform] | BEN-2293 (in clinical trial phase I) | For atopic dermatitis | Richardson et al. (2020), Bess et al. (2022), Jayatunga et al. (2022) |
| BenevolentAI [Benevolent Platform] and Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield | BEN-34712 (company progresses this molecule for amyotrophic lateral sclerosis | An oral, potent, and selective brain penetrant RARɑ𝛃 (retinoic acid receptor alpha beta) biased agonist | Benevolent (2023) |
| Relay Therapeutics [Dynamo Platform] | RLY-1971/RG-6433 (in clinical trial phase I) | For solid tumors | Jayatunga et al. (2022) |
| Relay Therapeutics [Dynamo Platform] | FGFR2 (in clinical trial phase I) | For FGFR2-driven cancers | |
| Nimbus Therapeutics | NDI-010976/GS-0976 (in clinical trial Phase II) | For nonalcoholic steatohepatitis (NASH) | |
| Pharos iBio [Chemiverse] | PHI-101 (in clinical trial phase I) | For acute myelogenous leukemia, platinum-resistant refractory ovarian cancer, and other cancers |
As far as DSP-1181 is concerned, as per the information on the internet, further research (clinical studies) on it in Japan has been stopped since the Phase I study did not meet the encouraging output (Schneider, 2018; Company Bap, 2022). Similarly, the clinical trials of BEN-2293 (a clinical-level asset from BenevolentAI) led to inclusive efficacy against atopic dermatitis, as per multiple websites. According to information on the company website, the company is currently evaluating the results of this trial for further processing of this drug candidate (Adcreviews, 2023; Benevolenet, 2023; BenevolentAI, 2023; Businesswire, 2023a; Clinicaltrialsarena, 2023).